Choroiditis

Summary

Choroiditis (MONDO:0001280) is a disease and 16 clinical trials. Top therapeutic interventions include cyclosporine and sotrastaurin. A subtype of optic choroid disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)
• Clinical trials: 16

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	choroiditis
Mondo ID	MONDO:0001280
MeSH	D002833
Orphanet	280892
DOID	DOID:11406
ICD-11	1884626736
NCIT	C35111
SNOMED CT	16553002
UMLS	C0008526
MedGen	40282
GARD	0004457
MedDRA	10036370
NORD	1601
Is cancer (heuristic)	no

Also known as: Choroiditides · choroiditis · Posterior Uveitis · posterior uveitis · posterior uveitis (disease)

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of optic choroid disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › uveal disorder › optic choroid disorder › choroiditis

Related subtypes (6): retinal dystrophies primarily involving Bruch’s membrane, choroidal sclerosis, central areolar choroidal dystrophy, ornithine aminotransferase deficiency, choroideremia, choroid neoplasm

Subtypes (4): infectious posterior uveitis, paraneoplastic uveitis, serpiginous choroiditis, multifocal choroiditis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

3 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Dexamethasone	Approved (phase 4)
Prednisolone	Approved (phase 4)
Prednisone	Approved (phase 4)
Bevacizumab	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 16.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	6
PHASE4	2
PHASE3	2
PHASE2	2
PHASE1/PHASE2	2
PHASE2/PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02764697	PHASE4	COMPLETED	Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients
NCT06613919	PHASE4	COMPLETED	Six-months Versus Nine-months ATT for Ocular TB
NCT00167583	PHASE3	COMPLETED	Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet’s Disease (INCYTOB)
NCT00333814	PHASE2/PHASE3	COMPLETED	A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis
NCT02746991	PHASE3	COMPLETED	Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis
NCT00615693	PHASE2	COMPLETED	Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis
NCT01280669	PHASE2	WITHDRAWN	Intravitreal Sirolimus as Therapeutic Approach to Uveitis
NCT01717170	PHASE1/PHASE2	UNKNOWN	Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study
NCT01789320	PHASE1/PHASE2	COMPLETED	Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis
NCT00908466	PHASE1	COMPLETED	Sirolimus as Therapeutic Approach to Uveitis
NCT05153057	Not specified	RECRUITING	Birdshot Chorioretinopathy : Prospective Follow-up and Immunogenetic Studies(CO-BIRD)
NCT00006188	Not specified	COMPLETED	Evaluation and Treatment of Patients With Inflammatory Eye Diseases
NCT00407316	Not specified	UNKNOWN	Quality of Life and Visual Function in Uveitis Patients
NCT00570830	Not specified	COMPLETED	Retisert and Cataract Surgery in Patients With Severe Uveitis
NCT03971279	Not specified	COMPLETED	Dexamethasone Intravitreal Implant (Ozurdex®) for Recurrent Vogt-Koyanagi-Harada (VKH) Disease Posterior Uveitis
NCT04126850	Not specified	UNKNOWN	Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CYCLOSPORINE	4	1
SOTRASTAURIN	2	3